FTC releases "pay-for-delay" study and continues to strongly recommend legislative action | Practical Law
The US Federal Trade Commission (FTC) continues to actively advocate for legislation proscribing "pay-for-delay" generic pharmaceutical settlements, with support from a FTC staff report that concludes that the prevalence of "pay-for-delay" deals is increasing and such deals cost consumers US$3.5 billion per year.